Publications by authors named "Yangpu Jia"
Background: Trastuzumab-targeted therapy is currently the standard of care for advanced human epidermal growth factor receptor 2 (HER2)-positive gastric cancer. However, the emergence of resistance to trastuzumab poses significant challenges.
Aim: To identify the key genes associated with trastuzumab resistance.
Article Synopsis
- Cisplatin resistance in gastric cancer is linked to gastric cancer stem cells (GCSCs), and researchers are exploring how microRNAs (miRNAs) like miR-21-5p contribute to this resistance.
- The study involved comparing CD44+ GCSCs with CD44- control cells, finding that miR-21-5p was highly expressed in GCSCs, promoting resistance by activating the TGF-β2/SMAD pathway.
- Knockdown of miR-21-5p reduced cisplatin resistance and inhibited the TGF-β2/SMAD pathway, suggesting that targeting miR-21-5p could help overcome resistance in gastric cancer treatment.
Piezo2 is a transmembrane-spanning ion channel protein implicated in multiple physiological processes, including cell proliferation and angiogenesis in many cell types. However, Piezo2 was recognized as representing a double-edged sword in terms of tumor growth. The prognostic and immunotherapeutic roles of Piezo2 in pan-cancer have not been reported.
View Article and Find Full Text PDFBackground: There was much hard work to study the trastuzumab resistance in HER2-positive gastric cancer (GC), but the information which would reveal this abstruse mechanism is little. In this study, we aimed to investigate the roles of tumor cell-derived CCL2 on trastuzumab resistance and overcome the resistance by treatment with the anti-CD40-scFv-linked anti-HER2 (CD40 ×HER2) bispecific antibody (bsAb).
Methods: We measured the levels of CCL2 expression in HER2-positive GC tissues, and revealed biological functions of tumor cell-derived CCL2 on tumor-associated macrophages (TAMs) and the trastuzumab resistance.